# A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder

> **NCT01914939** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 92 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Oxytocin
- **BEHAVIORAL:** Social Skills focused CBT
- **BEHAVIORAL:** Stress management/relaxation training
- **DRUG:** placebo drug

## Key facts

- **NCT ID:** NCT01914939
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01914939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01914939, "A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT01914939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*